Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

Macut, Djuro; Antić, Ivana Božić; Bjekić-Macut, Jelica; Panidis, Dimitrios; Τζιόμαλος, Κωνσταντίνος; Milutinović, Danijela Vojnović; Stanojlović, Olivera; Kastratović-Kotlica, Biljana; Petakov, Мilan; Milić, Nataša

doi:10.1007/bf03401401

Cited by 19 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with WC, TG was included in LAP, and it is reasonable to speculate that the two LAP components—that is, enlarged abdominal fat depots and increased TG concentration—are each an indication that available lipid fuels have exceeded the individual's capacity to buffer and safely store this major form of acquired energy [ 27 ]. Therefore, LAP can replace various clinical indicators of lipid accumulation and become a prerequisite for the diagnosis of metabolic syndrome [ 46 , 47 ]. LAP has been shown to be able to identify various diseases such as insulin resistance, CVDs [ 48 ], polycystic ovary syndrome [ 46 ], and hypertension and to assist in defining the concept of systemic fat abdominal visceral adipose tissue separation [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, LAP can replace various clinical indicators of lipid accumulation and become a prerequisite for the diagnosis of metabolic syndrome [ 46 , 47 ]. LAP has been shown to be able to identify various diseases such as insulin resistance, CVDs [ 48 ], polycystic ovary syndrome [ 46 ], and hypertension and to assist in defining the concept of systemic fat abdominal visceral adipose tissue separation [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals

Zhang

Liu

et al. 2021

International Journal of Endocrinology

View full text Add to dashboard Cite

Objective. To explore the anthropometric indicators suitable for screening for nonalcoholic fatty liver disease (NAFLD) in the elderly population. Methods. This cross-sectional study screened subjects over 65 years, who had undergone a physical examination in 2019. Their height, weight, waist circumference, and fasting blood glucose and triglyceride levels were measured. Body mass index (BMI), waist circumstance (WC), waist-to-height ratio (WHtR), relative fat mass (RFM), ponderal index (PI), conicity index (CI), lipid accumulation product (LAP), and body shape index (ABSI) were calculated. Statistical analyses were performed using the Chi-square test, logistic regression, and receiver operating characteristic (ROC) curve. Subjects. Of a total of 4985 subjects, 1173 diagnosed with NAFLD and 3812 without NAFLD were included. Results. The NAFLD group had increased BMI, WC, WHtR, RFM, PI, CI, and LAP. ABSI was only significantly different in males between the groups. Logistic regression analysis showed that RFM was an effective prognostic factor for males with NAFLD, and LAP, BMI, and WC were effective prognostic factors for females. ROC curve analysis showed that LAP played a significant role in the prediction of NAFLD. Conclusion. LAP is closely related to the occurrence of NAFLD and could be an efficient screening and treatment tool for NAFLD in the elderly people. Lay Summary. We conducted a screening and study of nonalcoholic fatty liver disease in the elderly population by determining the association between obesity indexes and nonalcoholic fatty liver disease. We found that LAP is practical, easy-to-measure tool for screening and studying NAFLD in the high-risk community elderly population, making it a valuable indicator in research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals

Zhang

Liu

et al. 2021

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Since its introduction in the literature, LAP has been shown to be a powerful index for identifying metabolic syndrome, insulin resistance, and NAFLD in several cohorts, as well as a reliable marker of CVD risk in women with PCOS [10][11][12][13][14][15][16]. Furthermore, a retrospective study by Ioachimescu et al, has reported that LAP, but not BMI, can predict the all-cause mortality in high CVD risk, non-diabetic patients attending a preventive cardiology clinic [26].…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, in this NHANES cohort, LAP exhibited better correlations with key CVD risk factors (i.e., heart rate and circulating levels of lipids and uric acid) compared to BMI [9]. Subsequently, LAP has been reported as a reliable marker of CVD risk in women with polycystic ovary syndrome (PCOS) and a useful index for recognizing insulin resistance, non-alcoholic fatty liver (NAFLD) and metabolic syndrome in various cohorts [10][11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 87%

Lipid accumulation product in relation to 10-year cardiovascular disease incidence in Caucasian adults: The ATTICA study

et al. 2018

View full text Add to dashboard Cite

2583 of the 3042 initial participants were reassessed during this follow-up An independent positive association between LAP and long-term CVD incidence in CVD-free Caucasian adults from the general population was revealed. LAP was positively associated with with 10-year CVD incidence, even after adjusting for hypertension, diabetes, hypercholesterolemia, smoking, physical activity, Mediterranean diet adherence, and key pro-inflammatory biomarkers (Hazard Ratios per 10 cm⋅mmol/L of LAP ranging from 1.1 to 1.21, p=0.04). LAP predicted CVD risk better than common obesity indices (BMI, WC, waist-to-hip, waist-to-height ratio). LAP is considered to expand on the concept of the hypertriglyceridemic waist as regards C VD risk

show abstract

“…However, despite the stratification of PCOS participants into 3 different phenotypes, the performance of the indexes was analyzed in that study only for the overall PCOS group. Other studies also found LAP to be a reliable index to identify metabolic syndrome in PCOS [30,47,48]. Indeed, although WC presents good correlation with abdominal adipose tissue, it cannot differentiate subcutaneous from visceral fat [49], an aspect that has major implications for cardiovascular disease [50,51].…”

Section: Discussionmentioning

confidence: 99%

Adiposity Indexes as Phenotype-Specific Markers of Preclinical Metabolic Alterations and Cardiovascular Risk in Polycystic Ovary Syndrome: A Cross-Sectional Study

Mario

Graff

Spritzer

2017

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a common condition in women of reproductive age. 2 PCOS phenotypes (classic and ovulatory) are currently recognized as the most prevalent, with important differences in terms of cardiometabolic features. We studied the performance of different adiposity indexes to predict preclinical metabolic alterations and cardiovascular risk in 234 women with PCOS (173 with classic and 61 with ovulatory PCOS) and 129 controls. Performance of waist circumference, waist-to-height ratio, conicity index, lipid accumulation product, and visceral adiposity index was assessed based on HOMA-IR ≥ 3.8 as reference standard for screening preclinical metabolic alterations and cardiovascular risk factors in each group. Lipid accumulation product had the best accuracy for classic PCOS, and visceral adiposity index had the best accuracy for ovulatory PCOS. By applying the cutoff point of lipid accumulation product<34, we identified a subgroup of patients without cardiometabolic alterations (P<0.05) in the group with classic PCOS, a population at higher risk for hypertension, dyslipidemia, and impaired glucose tolerance. In ovulatory PCOS, visceral adiposity index ≥ 1.32 was capable of detecting women with significantly higher blood pressure and less favorable glycemic and lipid variables as compared to ovulatory PCOS with lower visceral adiposity index (P<0.05). These results suggest LAP ≥ 34 as the best marker for classic PCOS, and VAI ≥ 1.32 for ovulatory PCOS women. Both indexes can be easily calculated with measures obtained in routine clinical practice and may be useful to detect cardiometabolic risk and secure early interventions.

show abstract

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

Cited by 19 publications

References 41 publications

Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals

Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals

Lipid accumulation product in relation to 10-year cardiovascular disease incidence in Caucasian adults: The ATTICA study

Adiposity Indexes as Phenotype-Specific Markers of Preclinical Metabolic Alterations and Cardiovascular Risk in Polycystic Ovary Syndrome: A Cross-Sectional Study

Contact Info

Product

Resources

About